Inactive Instrument

Press Releases Therapix Biosciences Ltd TEL AVIV STOCK EXCHANGE

Equities

IL0010951403

End-of-day quote TEL AVIV STOCK EXCHANGE Other stock markets
- ^ILa	-

Apr. 11	SciSparc Ltd. signed a merger agreement to acquire remaining stake in Automax Motors Ltd.	CI
Apr. 01	SciSparc Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

SciSparc to Acquire AutoMax	Apr. 11	GL
SciSparc: MitoCareX Unveils Groundbreaking Discovery of Small Molecule Structure in Anti-Cancer Research	Mar. 21	GL
SciSparc Granted Another Patent, Strengthening its Core Technology in Canada	Mar. 18	GL
SciSparc Granted Another Patent, Strengthening its Core Technology in Canada	Mar. 18	AQ
SciSparc Achieves Major Milestone with First Patient Dosed in Autism Spectrum Disorder Clinical Trial	Mar. 14	GL
SciSparc : MitoCareX Update - Form 6-K	Mar. 13	PU
SciSparc: MitoCareX Reveals Promising Results with Discovery of Novel Anti-Cancer Small Molecule Structure	Mar. 12	GL
SciSparc: MitoCareX Reveals Promising Results with Discovery of Novel Anti-Cancer Small Molecule Structure	Mar. 12	AQ
SciSparc Announces Enrollment of First Patient for its Clinical Trial for Children with Autism Spectrum Disorder	Mar. 08	GL
SciSparc Announces Enrollment of First Patient for its Clinical Trial for Children with Autism Spectrum Disorder	Mar. 08	AQ
SciSparc Granted Patent for Core Technology in Multiple Jurisdictions in Europe	Mar. 07	GL
SciSparc Granted Patent for Core Technology in Multiple Jurisdictions in Europe	Mar. 07	AQ
SciSparc Issued Canadian Patent for Opioids Reduction Use in Pain Management Technology	Mar. 06	GL
SciSparc Delivers Treatment for Autism Spectrum Disorder Clinical Trial Enabling Commencement of Dosing	Feb. 29	GL
SciSparc Delivers Treatment for Autism Spectrum Disorder Clinical Trial Enabling Commencement of Dosing	Feb. 29	AQ
SciSparc-Clearmind Partnership Yields Three New International Patent Applications for MDMA, Ibogaine and Ketamine Compounds	Feb. 27	GL
SciSparc-Clearmind Partnership Yields Three New International Patent Applications for MDMA, Ibogaine and Ketamine Compounds	Feb. 27	AQ
Clearmind Medicine Submits Three International Patent Applications for Next Generation Classical Psychedelic-Based Compounds	Feb. 21	AQ
SciSparc and Clearmind Continue to Strengthen International Patent Portfolio with Next Generation Classic Psychedelic-Based Compounds	Feb. 20	GL
Clearmind Medicine Submits Three International Patent Applications for Next Generation Classic Psychedelic-Based Compounds	Feb. 20	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Therapix Biosciences Ltd TEL AVIV STOCK EXCHANGE

Equities

IL0010951403

Press Releases

Filters